Comparison · NCT02028676-5ef437da
Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Once-daily ABC+3TC vs Twice-daily ABC+3TC: Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV. Trial comparisons, record NCT02028676-5ef437da. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02028676-5ef437da
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.17 | 0.133 | 0.213 | wilson | |
| Risk in group 2 | 0.162 | 0.126 | 0.206 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00748 | -0.0491 | 0.064 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.745 | 1.47 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.702 | 1.59 | log | |
| Number needed to treat, for one more participant with the outcome on Once-daily ABC+3TC than on Twice-daily ABC+3TC | 134 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Once-daily ABC+3TC | Other Names:~ABC: abacavir: Ziagen 3TC: lamivudine: Epivir ABC+3TC co-formulated: Kivexa | 57 | 336 | OG000 |
| Group 2 | Twice-daily ABC+3TC | Other Names:~ABC: abacavir: Ziagen 3TC: lamivudine: Epivir ABC+3TC co-formulated: Kivexa | 54 | 333 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
- Description
- Number of participants with a new grade 3 or 4 adverse event (AE), not solely related to HIV, to be analysed using time-to-event methods
- Time frame
- Median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
- NCT number
- NCT02028676
- Phases
- PHASE4
- Conditions
- Human Immunodeficiency Virus
- Interventions
Clinically Driven Monitoring (CDM), Laboratory plus Clinical Monitoring (LCM), Arm A: ABC+3TC+NNRTI, Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance, Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance, Once-daily ABC+3TC, Twice-daily ABC+3TC, Continued cotrimoxazole prophylaxis, Stopped cotrimoxazole prophylaxis
- Lead sponsor
- Medical Research Council
- Results first posted
- 2014-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02028676?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02028676-5ef437da